Eyestem to begin human trials for its pioneering Dry AMD treatment
Eyestem, a cell therapy company at the forefront of regenerative therapy, has received approval from India’s Central Drugs Standards Control Organisation (CDSCO) to commence human trials for Eyecyte RPE, aimed at combating geographic atrophy arising from dry age-related macular degeneration (AMD).
Dr Jogin Desai, Founder and Chief Executive Officer, Eyestem, said in a statement, “The commencement of human trials represents a significant and proud moment for all of us at Eyestem. Being a purpose-driven company, our commitment is to ensure that Eyecyte RPE reaches a much larger patient base than most cell and gene therapies worldwide. Our cell therapy platform has the ability to create products of the highest quality at scale, and we look forward to validating this hypothesis with our flagship product.”
“We are delighted to be part of this pioneering effort in this area from our country. The LVP team is solidly behind this project and are optimistic about its success,” said Gullapalli N Rao, Chairman, Founder, L. V. Prasad Eye Institute, Hyderabad.
Dry AMD, a leading cause of vision loss in the ageing population of people over 50, has long been a challenge due to the limited availability of effective treatments and the high costs associated with emerging therapeutic options. However, Eyestem’s Eyecyte RPE therapy, which aims to replace lost or damaged retinal pigment epithelium (RPE) cells, represents a transformational shift in aiming to tackle the disease. It aims to preserve and potentially improve sight for
